Georgette Kairanga, APRN
Psychiatric/Mental Health · Overland Park, KSNPI 1861008732
Payments from drug & device makers
Across 837 payments — averaging $15.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$2K
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$1K
- Neurocrine Biosciences, Inc.$997
- plus $5K from 15 others
What the payments were for
- Food & beverage$12,63699%
- Education$641%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 92 | $1,705 |
| AbbVie | 121 | $1,651 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 92 | $1,365 |
| Otsuka America Pharmaceutical, Inc. | 78 | $1,172 |
| Johnson & Johnson | 46 | $1,064 |
| Neurocrine Biosciences, Inc. | 50 | $997 |
| Teva Pharmaceuticals USA, Inc. | 83 | $881 |
| Vanda Pharmaceuticals Inc. | 81 | $871 |
| Indivior Inc. | 30 | $596 |
| Axsome Therapeutics, Inc. | 35 | $531 |
| Sunovion Pharmaceuticals Inc. | 29 | $510 |
| Lundbeck LLC | 40 | $502 |
| E.r. Squibb & Sons, L.L.C. | 39 | $481 |
| Noven Therapeutics, LLC | 8 | $129 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $85 |
| Supernus Pharmaceuticals, Inc. | 2 | $44 |
| Neuronetics, Inc. | 1 | $30 |
| Merck | 2 | $28 |
| Biogen | 1 | $21 |
| Almatica Pharma LLC | 1 | $19 |
| Eisai Inc. | 1 | $15 |
How this compares
$12,700 in reported general payments places this provider in the 95th percentile of 404 psychiatric/mental health providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 50 | $139,074 |
| Austedo XrDeutetrabenazine | 12 | $76,123 |
| Abilify MaintenaAripiprazole | 26 | $75,867 |
| AristadaAripiprazole Lauroxil | 19 | $61,430 |
| VraylarCariprazine Hcl | 36 | $56,628 |
| RexultiBrexpiprazole | 23 | $35,450 |
| FanaptIloperidone | 12 | $13,669 |
| Aripiprazole | 83 | $10,209 |
| TrintellixVortioxetine Hydrobromide | 15 | $7,584 |
| Quetiapine Fumarate | 203 | $4,002 |
| Divalproex Sodium ErDivalproex Sodium | 49 | $2,928 |
| Clozapine | 33 | $2,679 |
| Trazodone Hcl | 205 | $2,187 |
| Hydroxyzine Hcl | 99 | $2,092 |
| Lurasidone Hcl | 22 | $2,019 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $1,064 | $139,07450 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,172 | $111,31749 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $881 | $76,12312 claims |
| Alkermes, Inc.Aristada | $1,705 | $61,43019 claims |
| AbbVieVraylar | $1,651 | $56,62836 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $871 | $13,66912 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $85 | $7,58415 claims |
| Almatica Pharma LLCSertraline Hcl | $19 | $73082 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 404 psychiatric/mental health providers in Kansas.
Other psychiatric/mental health in Overland Park
- Theresa MuellerOverland Park$14K
- Omozuwa OmigieOverland Park$10K
- Susan ClavetteOverland Park$9K
- Laura YoungOverland Park$5K
- Eric ThomasonPittsburg$333K
- Belinda BagbyHutchinson$39K
- Hayley KnappWichita$31K
- Jennifer KubinBaldwin City$26K
- Uyen DinhPittsburg$20K
- Louise MuhoziKansas City$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.